Effects of corilagin on proliferation,migration,invasion and apoptosis of human hepatoma cells
Gao Jinting,Jiang Mi,Xu Jie,Xiong Jun
DOI: https://doi.org/10.3760/cma.j.cn421213-20211215-01371
2022-01-01
Abstract:Objective:To investigate the effects of Bufalin, AMD3100 as a drug, alone or in combination, on cell proliferation, migration, apoptosis and CD133 protein expression after acting on gallbladder cancer cell line (GBC-SD).Methods:Totally, 20 specimens of wax blocks of gallbladder cancer surgically resected at our hospital from January 2017 to December 2021 were collected, and the differences in the expression levels of CD133 in tumor tissues as well as in paracancerous tissues were detected by immunohistochemical techniques. GBC-SD cells were treated with different concentrations of Bufalin (80, 160, 320 nmol/L); AMD3100 (10, 20, 40 μmol/L) and the combination (Bufalin 160 nmol/L+ AMD3100 20 μmol/L). Cell counting kit-8 (CCK-8) method was used to observe the effect of drugs on tumor cell proliferation. Transwell method was used to detect tumor cell migration ability. Annexin V/propidium iodide (PI) method was used to detect apoptosis, and flow cytometry was used to detect CD133 expression. Rates were compared by χ2 test, and one-way and two-way ANOVAs were used for comparisons between groups. Results:The positive expression rate of CD133 molecules in human gallbladder cancer tissues was 85%, which was significantly higher than that of 30% in paraneoplastic tissues. The expression of CD133 molecules was localized in the cytoplasm and nucleus ( χ2=10.23, P<0.01). The cell proliferation of the experimental group was significantly inhibited by Bufalin (80, 160, 320 nmol/L) after 24, 48, 72 h as compared with the control ( F=21.389, 57.231, 73.444, P<0.05). The number of migrating cells after treatment of Bufalin with 160 nmol/L was (114.33±5.51), which was significantly reduced compared to the control group (270.67±13.65, F=241.989, P<0.01). The expression level of CD133 molecules was (1.48±0.14) was lower in Bufalin group than that in the control group (3.22±0.46, F=202.589, P<0.01), and the apoptosis rate (32.57±0.69)% was elevated compared to the control group [(16.35±0.33)%, F=171.288, P<0.01]. In the AMD3100 group, cell proliferation was inhibited in 20 μmol/L at 48 h [(87.58±7.10)%], 40 μmol/L at 48 h [(67.84±0.75)%, F=57.231, P<0.05] and 40 μmol/L at 72 h [(72.57±10.23)%, F=73.444, P<0.05] compared to the control group. After treatment with AMD3100 at 40 μmol/L, the number of migrating cells was significantly reduced [(193.33±8.08) cells] compared to the control group [(270.67±13.65) cells, F=241.989, P<0.01]. The expression level of CD133 molecules was (3.07±0.11) in the experimental group and (3.22±0.46) in the control group without reduction ( F=202.589, P>0.05). The apoptosis rate was (16.35±0.33)% in the control group and (16.37±1.81)% in the experimental group did not increase ( F=171.288, P>0.05). Cell proliferation was inhibited in the combination group (Bufalin 160 nmol/L+ AMD3100 20 μmol/L) compared with the control group at all time points (24, 48, 72 h, F=21.389, 57.231, 73.444, P<0.05). The number of migrating cells in the control group and experimental group was (270.67±13.65) and (133.67±6.50) respectively, and the difference was statistically significant ( F=241.989, P<0.01). The expression level of CD133 molecule (2.19±0.68) in the experimental group was lower than that in the control group (3.22±0.46, F=202.589, P<0.01). The apoptosis rate was elevated in the experimental group[(33.58±1.67)%] compared to the control group [(16.35±0.33)%, F=171.288, P<0.01]. Conclusion:CD133 was positively expressed in GBC-SD cells, and the positive expression rate was significantly higher in gallbladder cancer tissues than in paraneoplastic tissues. Bufalin and AMD3100 inhibited the proliferation and migration of gallbladder cancer cells. Bufalin alone and in combination with AMD3100 inhibited the proliferation and migration of gallbladder cancer cells, promoted apoptosis, and inhibited CD133 molecule expression.